No link between BMI and surgical outcome in esophageal cancer

Share this content:

Although body mass index (BMI) has been associated with inferior outcomes in gastrointestinal malignancies, it appears to have no bearing on surgical complications or survival in patients with esophageal adenocarcinoma who underwent esophagectomy after neoadjuvant chemoradiotherapy (nCRT).

An analysis of 303 such patients uncovered no difference in overall survival or disease-free survival associated with BMI. Kenneth L. Meredith, MD, of the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida, and fellow investigators also reported in Journal of Gastrointestinal Surgery that they found no differences in postoperative complications or mortality among the patients, who had been classified into four groups based on BMI:

  • ≤25
  • 25-30
  • >30-35
  • >35

Multivariate analysis revealed that none of the following factors were prognostic for worse overall or disease-free survival: BMI, age, gender, type of surgery, or year of diagnosis. However, a higher tumor stage and a less than complete response to nCRT were prognostic for worse overall and disease-free survival.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs